Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

Chiara C Bortolasci; Wolfgang Marx; Adam J Walker; Kyoko Hasebe; Bianca E Kavanagh; Margaret J Morris; Mohammadreza Mohebbi; Alyna Turner; Laura Gray; Lesley Berk; Ken Walder; Michael Berk; Olivia M Dean

doi:10.1136/bmjopen-2019-035080

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

Chiara C Bortolasci, Wolfgang Marx, Adam J Walker, Kyoko Hasebe, Bianca E Kavanagh, Margaret J Morris, Mohammadreza Mohebbi, Alyna Turner, Laura Gray, Lesley Berk, Ken Walder, Michael Berk, Olivia M Dean

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

62 Downloads (Pure)

Abstract

INTRODUCTION: Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.

METHODS AND ANALYSIS: PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration's 'Risk of Bias' tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2 model.

ETHICS AND DISSEMINATION: This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.

TRIAL REGISTRATION NUMBER: CRD42020153292.

Original language	English
Article number	e035080
Pages (from-to)	e035080
Journal	BMJ Open
Volume	10
Issue number	3
DOIs	https://doi.org/10.1136/bmjopen-2019-035080
Publication status	Published - 19 Mar 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmjopen-2019-035080Licence: CC BY-NC

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysisFinal published version, 259 KBLicence: CC BY-NC

Cite this

Bortolasci, C. C., Marx, W., Walker, A. J., Hasebe, K., Kavanagh, B. E., Morris, M. J., Mohebbi, M., Turner, A., Gray, L., Berk, L., Walder, K., Berk, M., & Dean, O. M. (2020). Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. BMJ Open, 10(3), e035080. Article e035080. https://doi.org/10.1136/bmjopen-2019-035080

@article{d194ad2e6aa04fe49c0786f07e6f12ef,

title = "Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis",

abstract = "INTRODUCTION: Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.METHODS AND ANALYSIS: PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration's 'Risk of Bias' tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2 model.ETHICS AND DISSEMINATION: This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.TRIAL REGISTRATION NUMBER: CRD42020153292.",

author = "Bortolasci, {Chiara C} and Wolfgang Marx and Walker, {Adam J} and Kyoko Hasebe and Kavanagh, {Bianca E} and Morris, {Margaret J} and Mohammadreza Mohebbi and Alyna Turner and Laura Gray and Lesley Berk and Ken Walder and Michael Berk and Dean, {Olivia M}",

note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2020",

month = mar,

day = "19",

doi = "10.1136/bmjopen-2019-035080",

language = "English",

volume = "10",

pages = "e035080",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "3",

}

Bortolasci, CC, Marx, W, Walker, AJ, Hasebe, K, Kavanagh, BE, Morris, MJ, Mohebbi, M, Turner, A, Gray, L, Berk, L, Walder, K, Berk, M & Dean, OM 2020, 'Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis', BMJ Open, vol. 10, no. 3, e035080, pp. e035080. https://doi.org/10.1136/bmjopen-2019-035080

TY - JOUR

T1 - Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

AU - Bortolasci, Chiara C

AU - Marx, Wolfgang

AU - Walker, Adam J

AU - Hasebe, Kyoko

AU - Kavanagh, Bianca E

AU - Morris, Margaret J

AU - Mohebbi, Mohammadreza

AU - Turner, Alyna

AU - Gray, Laura

AU - Berk, Lesley

AU - Walder, Ken

AU - Berk, Michael

AU - Dean, Olivia M

PY - 2020/3/19

Y1 - 2020/3/19

N2 - INTRODUCTION: Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.METHODS AND ANALYSIS: PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration's 'Risk of Bias' tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2 model.ETHICS AND DISSEMINATION: This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.TRIAL REGISTRATION NUMBER: CRD42020153292.

AB - INTRODUCTION: Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.METHODS AND ANALYSIS: PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration's 'Risk of Bias' tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2 model.ETHICS AND DISSEMINATION: This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.TRIAL REGISTRATION NUMBER: CRD42020153292.

UR - http://www.scopus.com/inward/record.url?scp=85082146771&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-035080

DO - 10.1136/bmjopen-2019-035080

M3 - Article

C2 - 32198305

SN - 2044-6055

VL - 10

SP - e035080

JO - BMJ Open

JF - BMJ Open

IS - 3

M1 - e035080

ER -

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Nutrition Research for Mental Health, Cognition and Eating Disorders

Cite this

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Related Projects

Nutrition Research for Mental Health, Cognition and Eating Disorders

Cite this